国新健康(000503) - 2023 Q1 - 季度财报

Financial Performance - Total operating revenue for Q1 2023 was ¥55,766,199.77, an increase of 47.0% compared to ¥37,951,381.37 in Q1 2022[11] - Total operating costs for Q1 2023 were ¥99,793,458.91, up 23.5% from ¥80,759,723.77 in the same period last year[11] - The company reported a net loss of ¥43,123,912.80 for Q1 2023, an improvement from a net loss of ¥49,421,999.82 in Q1 2022[11] - The net profit for the current period is -43,866,780.96, compared to -49,422,023.57 in the previous period, showing an improvement[14] - The total comprehensive income for the current period is -44,125,283.59, compared to -49,442,066.65 in the previous period[14] - Basic and diluted earnings per share are both -0.0484, an improvement from -0.0545 in the previous period[14] - Net loss attributable to shareholders was ¥-43,865,115.01, improving by 11.25% from ¥-49,423,957.16 year-over-year[27] Cash Flow and Liquidity - Cash and cash equivalents decreased to ¥116,974,970.15 from ¥169,465,147.63 at the beginning of the year, a decline of 30.9%[3] - The net cash flow from operating activities is -83,500,999.68, an improvement from -101,791,799.62 in the previous period[19] - Cash inflows from operating activities totaled 48,705,936.60, up from 23,618,915.13 in the previous period[19] - Cash outflows from operating activities increased to 132,206,936.28 from 125,410,714.75 in the previous period[19] - The ending cash and cash equivalents balance is 112,821,001.03, down from 238,032,127.40 in the previous period[21] Assets and Liabilities - Total assets decreased to ¥1,063,525,048.13 from ¥1,104,696,713.12, a reduction of 3.7%[10] - Total liabilities increased slightly to ¥393,847,260.24 from ¥391,707,776.39, reflecting a 0.5% rise[7] - The company’s equity attributable to shareholders decreased to ¥668,058,887.59 from ¥711,368,370.48, a decline of 6.1%[7] - Total assets at the end of the reporting period were ¥1,063,525,048.13, a decrease of 3.73% from ¥1,104,696,713.12 at the end of the previous year[27] Research and Development - Research and development expenses for Q1 2023 were ¥967,945.83, down 52.5% from ¥2,042,652.21 in Q1 2022[11] - Research and development expenses decreased by 52.61% to ¥967,945.83, reflecting differences in project stages[32] Market Strategy and Future Plans - The company plans to focus on market expansion and new product development in the upcoming quarters[12] - Sales expenses increased by 77.33% to ¥8,515,293.56, driven by enhanced market expansion efforts[32] Shareholder Information - The total number of common shareholders at the end of the reporting period is 57,745, with the largest shareholder, China Oceanwide Holdings, holding 26.00% of shares, equating to 235,702,593 shares[37] - The second largest shareholder, Jiao Yu, holds 1.03% of shares, amounting to 9,299,444 shares, while Hong Kong Central Clearing Limited holds 1.02% with 9,256,810 shares[37] Investments and Financing - The company experienced a 100% increase in short-term borrowings, totaling ¥90,113,307.28, due to new bank credit loans[32] - The net cash flow from financing activities is 43,866,996.67, compared to -715,521.65 in the previous period[21] - The company received government subsidies amounting to ¥312,113.78, primarily due to personal income tax refunds[29] - Investment income was reported at ¥335,268.91, a significant turnaround from a loss of ¥-537,717.96 in the previous year, due to profit recognition from equity method accounting[32] Contractual Adjustments - A contract adjustment was made for a software development project, reducing the total price from RMB 13,082,300 to RMB 12,432,300[43] - The company has decided to waive its preemptive rights for capital increase in its associate company, Beijing Yiyong Technology Co., Ltd.[44]